Bladder-cancer-associated mutations in <i>RXRA</i> activate peroxisome proliferator-activated receptors to drive urothelial proliferation.

Comparing the number of doublings per passage between the two conditions, we found the difference to be highly significant (paired t test p=0.0003), confirming gain-of-function with the mutant allele.

also in 132,142 other papers